双侧经颅磁刺激改善卒中恢复期患者上肢运动功能的单盲随机临床试验方案
本研究为前瞻性、单盲、随机对照试验,计划纳入76例卒中恢复期上肢运动障碍患者,按1:1:1:1随机分为联合组、低频组、高频组和对照组,每组19例,在常规康复基础上分别接受不同方案rTMS或假刺激。主要结局为FMA-UE、潜伏期和血清BDNF水平,次要结局包括NIHSS、Brunnstrom分期、MAS、MBI、CMCT、proBDNF和MMP-9,并记录不良事件。
要点
- 联合组接受患侧10 Hz rTMS及健侧1 Hz rTMS,低频组为健侧1 Hz rTMS加对侧假刺激,高频组为患侧10 Hz rTMS加对侧假刺激,对照组为双侧假刺激。
- 主要结局为FMA-UE、潜伏期和血清BDNF水平,评估时间点为基线、治疗2周后及治疗后第6周随访。
- 研究将记录头痛和癫痫发作等不良事件。
核心结论
- 本研究旨在探讨不同rTMS方案治疗卒中恢复期上肢运动障碍的疗效和安全性,并基于BDNF等生物标志物探索潜在机制。
研究设计与样本
- 前瞻性、单盲、随机对照试验,计划纳入76例卒中恢复期上肢运动障碍患者,按1:1:1:1随机分为联合组、低频组、高频组和对照组,每组19例。
主要发现
- 所有组均接受常规康复;联合组在此基础上接受健侧1 Hz rTMS和患侧10 Hz rTMS,低频组接受健侧1 Hz rTMS和对侧假刺激,高频组接受患侧10 Hz rTMS和对侧假刺激,对照组接受双侧假刺激。
- 评估在基线、治疗2周后及治疗后第6周随访时进行。
- 主要结局为FMA-UE、潜伏期和血清BDNF水平;次要结局为NIHSS、Brunnstrom分期、MAS、MBI、CMCT、proBDNF和MMP-9水平。
- 研究全程记录头痛和癫痫发作等不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No consensus currently exists regarding the optimal protocol for repetitive transcranial magnetic stimulation (rTMS) treatment of upper-extremity motor dysfunction after stroke. Studies have shown that combined low- and high-frequency stimulation (LF-HF-rTMS) of the bilateral cerebral hemispheres is more effective than sham stimulation or stimulation of one cerebral hemisphere alone in treating motor dysfunction in the subacute stage of stroke. The efficacy of this protocol in the convalescence phase of stroke has rarely been reported, and its mechanism of action has not been clarified. In this study, we designed a prospective, single-blind, randomized controlled trial to investigate the efficacy and safety of different stimulation regimens for the treatment of upper extremity motor disorders in patients with convalescent stage stroke and aimed to explore the underlying mechanisms based on biomarkers such as brain-derived neurotrophic factor (BDNF). METHODS: Seventy-six subjects will be randomly divided into combined, low-frequency, high-frequency, and control groups based on the proportion of 1:1:1:1, with 19 cases in each group. All groups will have conventional rehabilitation, on top of which the combined group will receive 1 Hz rTMS in the unaffected hemisphere and 10 Hz rTMS in the affected hemisphere. The low-frequency group will be administered 1 Hz rTMS in the unaffected hemisphere and sham stimulation in the contralateral hemisphere. The high-frequency group will be administered 10 Hz rTMS in the affected hemisphere and contralateral sham stimulation. The control group will receive bilateral sham stimulation. Assessments will be performed at baseline, after 2 weeks of treatment, and at post-treatment follow-up at week 6. The primary outcomes are FMA-UE (Fugl-Meyer assessment-upper extremity), latency, and serum BDNF levels. The secondary outcomes are the National Institute of Health Stroke Scale (NIHSS), Brunnstrom staging (BS), modified Ashworth scale (MAS), Modified Barthel Index (MBI), central motor conduction time (CMCT), precursor proteins of mature BDNF (proBDNF), and matrix metalloproteinase-9 (MMP-9) levels. Adverse events, such as headaches and seizures, will be recorded throughout the study. DISCUSSION: The findings of this study will help develop optimal stimulation protocols for motor recovery in stroke patients and identify biomarkers that respond to post-stroke motor rehabilitation, for better guidance of clinical treatment. TRIAL REGISTRATION: The study protocol was passed by the Medical Research Ethics Committee of the General Hospital of Ningxia Medical University on January 1, 2022 (no. KYLL-2021-1082). It was registered into the Chinese Clinical Trials Registry on May 22, 2022 (no. ChiCTR2200060201). This study is currently in progress.
引用
- Huang Y, Lin R, Li H, et al. Protocol for a single-blind randomized clinical trial to test the efficacy of bilateral transcranial magnetic stimulation on upper extremity motor function in patients recovering from stroke. Trials. 2023. PMID: 37735708. doi:10.1186/s13063-023-07584-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。